Loading...
XSHE
002872
Market cap227mUSD
Jul 10, Last price  
4.88CNY
1D
0.62%
1Q
-3.17%
IPO
-79.04%
Name

Tiansheng Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XSHE:002872 chart
P/E
P/S
3.02
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
-6.94%
Revenues
514m
-9.76%
1,004,120,0191,421,960,0601,663,784,3421,843,015,2792,086,931,5562,261,414,3762,171,439,9221,679,540,4671,202,746,110736,685,771736,685,771606,992,213606,992,213579,334,658569,712,742514,087,696
Net income
-55m
L-36.59%
109,987,797125,948,056164,573,153191,977,872224,496,965247,332,8668,860,543-223,979,238-490,732,3640-67,805,3870-90,563,420-93,073,691-87,403,825-55,423,546
CFO
43m
-14.31%
145,057,10057,059,300191,988,710213,538,862506,677,2400153,986,687144,208,286189,754,32918,971,79289,184,806-24,561,76150,146,53642,969,395
Dividend
Aug 22, 20180.236 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Tiansheng Pharmaceutical Group Co., Ltd. is engaged in the manufacturing and distribution of pharmaceutical products. The company supplies a broad spectrum of medications that address various therapeutic areas, including respiratory, digestive, cardiovascular and cerebrovascular, pediatric, gynecological, orthopedic, oncological, hepatobiliary, hematological, surgical, and diabetic conditions, among others. This enterprise was established in 2001 and its headquarters are located in Chongqing, China.
IPO date
May 19, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT